Overview
- Australia’s Therapeutic Goods Administration approved and listed the software on the Australian Register of Therapeutic Goods, allowing legal activation once Apple sets a launch date.
- The system analyzes photoplethysmography data over rolling 30‑day periods to detect signals linked to chronic hypertension, then advises confirmation with a cuff and clinical follow‑up.
- Eligibility applies to adults 22 or older who are not pregnant and have no prior hypertension diagnosis, with support limited to Apple Watch Series 9 or later or Apple Watch Ultra 2 or later on watchOS 26 paired with an iPhone 11 or newer.
- Hypertension notifications are already available in more than 150 countries, and Australia’s clearance aligns the country with those markets.
- Apple cites independent validation involving thousands of participants, and the company and medical experts estimate the feature could help notify over one million people who may be undiagnosed.